340 related articles for article (PubMed ID: 33299657)
1. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C; Hagege A; Borchiellini D; Thamphya B; Rastoin O; Ambrosetti D; Iovanna J; Rioux-Leclercq N; Porta C; Negrier S; Ferrero JM; Chamorey E; Pagès G; Dufies M
Oncoimmunology; 2020 Nov; 9(1):1846901. PubMed ID: 33299657
[TBL] [Abstract][Full Text] [Related]
2. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
3. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
4. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
5. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
[TBL] [Abstract][Full Text] [Related]
6. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
7. Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
Larrinaga G; Solano-Iturri JD; Errarte P; Unda M; Loizaga-Iriarte A; Pérez-Fernández A; Echevarría E; Asumendi A; Manini C; Angulo JC; López JI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562338
[TBL] [Abstract][Full Text] [Related]
8. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Széles Á; Fazekas T; Váncsa S; Váradi M; Kovács PT; Krafft U; Grünwald V; Hadaschik B; Csizmarik A; Hegyi P; Váradi A; Nyirády P; Szarvas T
Cancer Immunol Immunother; 2023 May; 72(5):1061-1073. PubMed ID: 36385210
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.
Kammerer-Jacquet SF; Brunot A; Lefort M; Bayat S; Peyronnet B; Verhoest G; Mathieu R; Lespagnol A; Mosser J; Laguerre B; Ravaud A; Bernhard JC; Dupuis F; Yacoub M; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
Clin Genitourin Cancer; 2019 Jun; 17(3):169-176.e1. PubMed ID: 30837208
[TBL] [Abstract][Full Text] [Related]
11. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients.
Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J
Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808
[TBL] [Abstract][Full Text] [Related]
12. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
[TBL] [Abstract][Full Text] [Related]
13. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.
Dufies M; Nollet M; Ambrosetti D; Traboulsi W; Viotti J; Borchiellini D; Grépin R; Parola J; Giuliano S; Helley-Russick D; Bensalah K; Ravaud A; Bernhard JC; Schiappa R; Bardin N; Dignat-George F; Rioux-Leclercq N; Oudard S; Négrier S; Ferrero JM; Chamorey E; Blot-Chabaud M; Pagès G
Theranostics; 2018; 8(9):2447-2458. PubMed ID: 29721091
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab.
Wakita N; Hinata N; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M
Anticancer Res; 2023 Feb; 43(2):841-847. PubMed ID: 36697079
[TBL] [Abstract][Full Text] [Related]
16. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
17. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.
Jiang W; Wang D; Liu X; Zheng W; Wen L; Shi H; Zhang H; Zhou A; Li C; Ma J; Zheng S; Shou J
Urol Oncol; 2021 Jan; 39(1):78.e9-78.e16. PubMed ID: 32988712
[TBL] [Abstract][Full Text] [Related]
20. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
